wait deliv promis miss lower guidanc
invest summari reiter neutral rate price
target follow ep miss manag lower
financi guidanc robust busi model said risk/reward
alreadi reflect compani valuat view could still becom
construct stock new product opportun exceed expect and/
 gener drug price improv
takeaway quarter total revenu
y/i row sale constant
currenc eu sale constant
currenc north america sale actual
adjust free cash flow y/i expect repay
debt matur next month util cash flow gener
remain commit investment-grad credit rate compani
expect leverag ratio year-end board put
statement form strateg review committe activ
evalu wide rang altern unlock true valu
one-of-a-kind platform board set timet evalu
altern assur altern
implement elabor call
 report ep factset consensu
estim decreas ep guidanc rang
factset consensu updat financi model
result decreas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti upsid downsid risk neutral invest thesi
risk downsid includ follow gener drug price continu declin
could come increas competit key product also custom
consolid given buy consortium power negoti better price
consortium could continu caus price fall although integr meda
progress integr fall behind rel expect could pressur
stock harder follow progress meda divis
gener lot public data avail report
quarter lack meaning gener launch could make hard
off-set sale declin matur product gener industri product shorter
life cycl brand drug gener part commod busi
risk upsid includ follow could receiv approv launch
advair and/or restasi year one combin product could provid
upsid potenti consensu expect would limited-opportun larg gener
opportun integr meda could progress faster expect higher amount
synergi captur faster synergi captur could drive upsid number mylan
brand drug biosimilar busi may move forward new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull-
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casegener drug price improveslaunch advairlaunch restasisbiosimilarslaunch scenario casegener drug price stablelaunch advairlaunch restasisbiosimilarslaunch line scenario casegener drug price declin furtherno launch advairno launch restasisbiosimilarslaunch scenario exhibit varianc analysi
million us except per share amount amount chang yoyamount chang yoyvariancecommentstot lower net sale north gross time project oper non oper pre-tax tax non-oper items- nm- nm- net averag oper cantor fitzgerald research compani estim exhibit catalyst event calendar
datedriverupcom biosimilar adalimumab w/ fkbema revefenacin potenti regulatori approv revefenacin symbicortfil biosimilar insulin aspart pk/pd biosimilar insulin aspart initi phase type eu year botoxmeet estrogen gx premarin meet launch gener post per advair submit eu biosimilar adalimumab w/ bioconsubmit regulatori file biosimilar stay launch settl term flixotid pmdieu market author applic submit inject businessreach global launch gener dealreach pre-tax oper effici year post depotind file initi phase symfi lo cimduoapprovalsbi end biosimilar trastuzumab eu decisionbi end biosimilar pegfilgrastim eu launch gener royalti bear licens earli herceptin trastuzumab biosimilarlaunch settlement date advair wixela restasisu per settlement ag biosimilar insulin glargin end depotnda revefenacin exclus endsaugust depotu patent expiresourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
million us except ep guidanc midpointcantor fitzgerald profit net dilut share cantor fitzgerald research compani expect mid-teen declin north american segment yoy high singl digit growth europ well rest world throughout complex gener trend lower singl digit gener util versu typic oral small intend repay debt includ euro matur novemb matur next year util cash gener expect year end leverag ratio reduc launch fulphila line expect complex product launch forecast gradual sustain contuinu experi interrupt product epipen suppli continu vari launch weight drive growth expect morgantown facil remedi activ drive lower product level neg impact oper relat expens gener copaxon lower price gener still see incent higher price option exhibit incom statement analysi
million except ep compound-annual-growth-rate year end decemb gross oper non-oper pre-tax tax minor interest net averag oper changetot cantor fitzgerald research compani report exclud purchas account relat amort litig settlement amort convert debt discount conting consider liabil clean energi invest acquisit relat cost restructur special item relat tax effect exclud purchas account amort litig settlement clean energi interest expens invest loss accret conting consider acquisit relat custom incent restructur relat cost special item relat tax effect fo adjust exclud purchas account amort litig settlement clean energi interest expens invest loss interest expens accret conting considerationli fair valu adjust acquisit relat cost restructur relat cost special item tax effect relat adjust exclud purchas account amort relat item acquisit relat item restructur relat cost special item litig settlement conting net interest expens pre-tax loss relat clean energi invest accret conting consider liabil relat tax effect adjust exclud purchas account amort relat item acquisit relat item restructur relat cost special item litig settlement otherconting net interest expens pre-tax loss relat clean energi invest accret conting consider liabil relat tax effect adjust exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb total changetot cantor fitzgerald research compani reportsspecialti includ brand revenu includ author gener product sale exhibit annual sale analysi
fiscal gener paragraph paragraph iv exclus opp risk-adjust acetylcystein acetadot inject nmnmnmnmnmnmnmnmpioglitazon actoplu salmeterol olmesartan hcl sodium chlorid inject rectal suppositori celebrex nmnmnmnmnmnmnmnmvareniclin chantix nmnmnmnmnmnmnmnmdesloratadin delayed-releas capsul chewabl inject hectorol kaletra nmnmnmnmnmnmnmnmpregabalin transderm system acid tablet dr sodium phosphat orapr extend releas prezista nmnmnmnmnmnmnmnmmilnacipran ethinyl estradiol silenor nmnmnmnmnmnmnmnmniacin extend release/simvastatin strattera nmnmnmnmnmnmnmnmsunitinib malat hcl treximet nmnmnmnmnmnmnmnmsildenafil citrat tablet tablet dimesyl piv cumul paragraph iv non-u asset global institut busi bionich gener cantor fitzgerald research compani report bold italic mean settlement exhibit analysi
decemb fiscal activitiesnet non-cash chang work capit net activitiesproce purchas capit sale sale market item net activitieslong-term oblig option proce purchas common net cash exchang balanc balanc cantor fitzgerald research compani report exhibit balanc sheet analysi
decemb fiscal cash market securities- account receiv inventori defer incom tax prepaid expens current total current properti plant equip intang asset total liabil sharehold equitytrad account incom tax current portion long-term dividend payable- current total current long term total common prefer addit paid retain less common stock treasuri total sharehold total liabil sharehold sourc cantor fitzgerald research compani report august
global pharmaceut compani develop licens manufactur market distribut gener brand name over-
the-count over-the-counter product varieti dosag form therapeut categori product portfolio includ approxim
product compani market countri territori
